Inventec's subsidiary, Good Future Biomedical Technology Corp., has collaborated with its group partner, Inventec Appliances Corp., to develop an automated circulating tumor cell detection system called "CircuXin" in response to the increasing demand for circulating tumor cell testing. Dr. Lin Chi-peng, the head of Good Future Biomedical, recently revealed that this system has been deployed in overseas markets and is gradually engaging with medical units in Thailand, Malaysia, and other regions. There is a good chance of penetrating the medical supply chains in these two countries, thereby strengthening the group's medical layout in the Southeast Asian market.
Dr. Lin pointed out that the team has been continuously brainstorming to upgrade this automated detection system to meet the huge demand for tumor cell testing in the country. The latest models, CATCH HT and CATCH II, can each detect up to 96 samples per day and simultaneously analyze six biomarkers, significantly enhancing testing capacity. It is expected to meet the market demand for precise and convenient cancer rapid testing.
Dr. Lin noted that the system can currently detect the "Top Ten Cancers," mainly by testing the blood of the subjects. During screening, red and white blood cells are removed from the samples to avoid interference with the test results. Through this system, the quantity of "tumor cells" in the subject's blood can be accurately determined, categorized into "healthy: 0-4 cells, moderate risk: 5-29 cells, high risk: 30 cells or more." Although the testing cost is relatively high, the accuracy is better, thus gaining cooperation from many medical institutions.
Dr. Lin admitted that besides relying on the team's expertise in medical technology, assistance from Yinghua Da engineers is needed to operate this system (CTC Circulating Tumor Cells) jointly. Through early screening, targeted effectiveness evaluation, and postoperative follow-up, tumors and cancer cells can be effectively reduced in size or in quantity.
According to data released by the World Health Organization, only 5% of the global population is truly healthy. Facing the rapidly growing demand for testing worldwide, the Inventec Group has also introduced the automated circulating tumor cell (CTC) detection equipment developed through the cooperation of its two subsidiaries. With an All-in-One design, it implements a fully automated testing mode from Sample-in to Data-out, allowing the CTC value and cancer risk analysis in the blood to be obtained through blood testing, becoming a pride of the biotechnology industry.
Dr. Lin revealed that multiple institutions, including Taipei Veterans General Hospital, have already purchased Good Future Biomedical's system equipment for in-hospital sample screening. Other individuals and hospitals still need to send samples to Good Future Biomedical's testing center for examination. However, with the continuous increase in domestic cooperative sampling units, it will be more convenient for individuals to use this system in the future. The system is currently expanding into overseas markets, with the initial focus on Thailand and Malaysia, and good news is expected later this year.
Resource (Mandarin):
